⌜ The Cover Story ⌝
Most NIH grants are not triaged for the science. They are triaged for the framing: vague innovation claims, underpowered statistics, citations that almost — but do not quite — support the claim. Reviewers see what the PI cannot. PayLineHQ runs your application through three independent reviewer simulations before NIH does, so you fix what they would have flagged, before they count.
§01
A triaged grant is a 9-month silence followed by a summary statement that describes weaknesses you could have caught in a week. The fix is not better science — most triaged science is good. The fix is seeing your application the way a reviewer sees it before the panel convenes.
PayLineHQ is a peer-review engine built on 25 years of reviewer psychology and the patterns that distinguish funded grants from triaged ones. It is not a writing assistant. It is the second pair of eyes you do not have on your own draft.
§02
From plain-language draft to certified submission package in five to seven business days. The PI provides the science; PayLineHQ provides the structure, the reviewer simulation, and the certification.
01
Plain language. We extract aims, mechanism, target institute, and commercialization angle. You stay the principal investigator.
02
Every section drafted to NIH conventions. Three independent reviewer personas score it before delivery. Weak spots come back with the receipts.
03
Three-pass quality review: science, NIH compliance, simulated impact score. If the score isn't competitive, we rewrite. You get a submission-ready package.
§03
An actual summary statement, generated for an SBIR Phase I application to NCI. Three reviewers, each with a different vantage. Concerns surfaced before the panel meets.
Department of Health & Human Services · Public Health Service
Summary Statement (simulated)
Overall impact score
Lower is better. Funding line for NCI SBIR is approximately 35.
Reviewers' resume
Significant strengths. The application addresses a clear unmet need with a well-designed experimental approach. The PI is well-qualified, preliminary data are compelling, and the commercialization narrative is plausible. Three concerns — articulated below — should be addressed before submission to maximize the impact score and increase the likelihood of funding within the current paylines.
Reviewer
R1 · Dr. Sarah Chen
Basic Scientist · Molecular Biology
Strengths
Concern
Innovation claim could be more precisely articulated against existing literature.
Reviewer
R2 · Dr. Marcus Williams
Translational Researcher · Oncology
Strengths
Concern
Sample size justification should include explicit statistical power calculation for primary endpoint.
Reviewer
R3 · Dr. Patricia Rodriguez
Biostatistician · Clinical Trials Design
Strengths
Concern
Missing-data handling plan for primary endpoint needs to be specified.
Certified for delivery. Three concerns surfaced; each can be addressed in a single revision pass before resubmission.
Generated · 02 ms · model v3.4
§04
Across every dimension a biotech founder actually evaluates when deciding whether to write the grant herself, hire a consultant, or pay for AI.
| Dimension | Human consultant | Generic AI | PayLineHQ |
|---|---|---|---|
| Cost | $5K – $15K | $20 – $50/mo | $2,500 + 3% if funded |
| Timeline | 4–8 weeks | Instant (unreviewed) | 5–7 business days |
| NIH expertise | Varies | Generic | ★ 25 yrs · $7M+ awarded |
| Peer review simulation | — | — | ★ Three reviewers, every grant |
| Citation verification | Manual | Hallucinations | ★ Five databases |
| FOA-specific compliance | Manual | — | Automated |
| Quality certification | — | — | ★ Three-pass mandatory |
| You retain IP | Yes | Unclear | Always — no co-author claim |
| Success-aligned pricing | — | — | ★ 3% only if funded |
★ Capabilities unique to PayLineHQ at the time of this issue.
§05
By Eddie Bannerman-Menson
Founder, COARE Holdings · DCLK1-targeted CAR-T for ovarian cancer
I have been writing NIH grants for a decade. My company is developing a DCLK1-targeted CAR-T cell therapy for platinum-resistant ovarian cancer, and the path to the clinic runs through non-dilutive funding — primarily SBIR and STTR.
For years I watched applications come back triaged for fixable reasons. Vague innovation framing. Underpowered statistics. A citation that did not quite support the claim it was attached to. Reviewers caught what I could not see, and there was no way to simulate their perspective before submission.
PayLineHQ is the tool I wished existed. It runs your application through three independent reviewer simulations using 25 years of NIH peer-review psychology, scores it against funded comparators, and tells you exactly what to fix before NIH does. The same engine now reviews every COARE submission.
If it works for me, it works for you.
§06
Two paths into the engine. Pick the one that matches your timeline. Both run the same simulation against the same reviewer panel.
Self-Serve · For hands-on PIs
$149/month
14-day free trial · cancel anytime
Submit-Ready · Done by us
$2,500 upfront
+ 3% success fee, paid only if funded
Phase II / Fast Track from $4,500 · R01 / R21 from $3,500 · Full pricing schedule
§07
More at the full FAQ →
⌜ Closing remarks ⌝
Begin a free trial in the app, or commission a Submit-Ready engagement. Either path opens with the same simulation.